PART I . Overview We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.Our oncology platform utilizes our systemic, non-viral ONCOPREX Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins tha...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001437749-26-010346 | EDGAR | 99K words |
| 2025-04-01 | 2024-12-31 | 0001437749-25-010311 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001437749-24-010426 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001437749-23-008847 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001437749-22-007680 | EDGAR | — |
| 2021-03-26 | 2020-12-31 | 0001437749-21-007317 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001437749-20-006522 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001564590-19-010279 | EDGAR | — |
| 2018-04-17 | 2017-12-31 | 0001564590-18-008342 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001437749-25-035191 | EDGAR | 30K words |
| 2025-08-14 | 2025-06-30 | 0001437749-25-026965 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001437749-25-016133 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034697 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001437749-24-025893 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001437749-24-017061 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001437749-23-031830 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001437749-23-024247 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001437749-23-015445 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001437749-22-027048 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001437749-22-020379 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001437749-22-012372 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-18 | 0001437749-26-008733 | EDGAR | 2K words |
| 2026-02-23 | 0001437749-26-004954 | EDGAR | — |
| 2026-02-10 | 0001437749-26-003577 | EDGAR | — |
| 2026-01-09 | 0001437749-26-000995 | EDGAR | — |
| 2026-01-07 | 0001437749-26-000694 | EDGAR | — |
| 2026-01-06 | 0001437749-26-000437 | EDGAR | — |
| 2025-12-23 | 0001437749-25-038601 | EDGAR | — |
| 2025-11-26 | 0001437749-25-036380 | EDGAR | — |
| 2025-11-21 | 0001437749-25-036016 | EDGAR | — |
| 2025-11-19 | 0001437749-25-035651 | EDGAR | — |
235 total filings indexed. 204 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001595248 |
| Ticker | GNPX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | TX |
| Website | https://www.genprex.com |
| Listed | 2018-03-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report